Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome
NCT02262338
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
6
Enrollment
INDUSTRY
Sponsor class
Conditions
Mucopolysaccharidosis II
Interventions
DRUG:
AGT-182
Sponsor
ArmaGen, Inc